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Purpose: To evaluate the efficacy of Ahmed glaucoma valve 
(AGV) implantation for neovascular glaucoma (NVG), in short, 
intermediate, and long term follow ups. 
Patients and Methods: The present study was a retrospective 
review of 23 eyes of 23 patients with NGV who underwent AGV 
implantation at Imam Hussein Medical Center, Tehran, Iran, 
between January 2008 and March 2017. Pre and post operative 
intraocular pressure (IOP), visual acuity, surgical success rate, 
number of medications, and complications were recorded. The 
primary outcome was surgical success  defined  in  terms of 
5 ≤ IOP ≤ 21 mmHg and at least 20 %  reduction  in  IOP without 
glaucoma medication (complete success), or with medications 
(qualified success). The sum of complete success and qualified 
success was reported as cumulative success. 
Results: The mean follow up period was 4.69 years (range, 
2-10 years). The mean IOP was significantly lower compared to 
preoperative mean at each postoperative visit up to three years 
(P < 0.001). The cumulative surgical success rate at 1 year, 2 years 
and 3 years were 91.3 %, 82.6 %, 78.3 % respectively. The mean 
number of drugs needed to control IOP was significantly lower 
compared to preoperative mean at each postoperative visit up to 
three years.
Conclusion: It seems that AGV insertion is a safe and effective 
surgical method to treat neovascular glaucoma with acceptable 
success rates up to three years post operatively. More prospective 
studies with higher number of participants are recommended 
to better evaluate the success rate of AVG implantation to treat 
patients with neovascular glaucoma.
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Introduction
Neovascular glaucoma (NVG) is a refractory 
and aggressive type of secondary glaucoma 
that is accompanied by iris and chamber 
angle neovascularization and often results in 
poor visual outcomes 1,2. This catastrophic 
form of glaucoma  has  been  reported  in 
many ocular  diseases,  especially in  diabetes 
mellitus, central retinal vein occlusion, and 
ocular  ischemic  syndrome  3,4. Fibrovascular 
tissue in the angle obstructs the trabecular 
meshwork and results in outflow resistance as 
well as peripheral anterior synechiae causing 
higher intraocular pressure 5. 
Intraocular pressure (IOP) lowering 
medications, anti vascular endothelial growth 
factor (VEGF) injections, and panretinal 
photocoagulation (PRP) are most of the time 
insufficient for controlling the intraocular 
pressure among these patients 5.  The use of 
glaucoma drainage devices has increased 
for treating neovascular glaucoma because 
the surgical failure of trabeculectomy even 
with antimetabolites usage is as high as 80 % 
6-9. These devises have a significantly lower 
frequency of adverse events in comparison 
with trabeculectomy 10.
Although cycloablation procedures can 
reduce the IOP among these patients but 
their complications such as phthisis are 
unacceptable 11-13. 
In the present study we aimed to evaluate the 
long-term results and success rate of AGV 
implementation in patients with neovascular 
glaucoma.
Patients and Methods
In this retrospective study, all neovascular 
glaucoma patients who underwent AGV 
insertion in Imam Hossein Medical Center, 
Tehran, Iran, between January 2008 and March 
2017 were included.  The study was  approval 
by the Ethics Committee of Shahid Beheshti 
University of Medical Sciences, Tehran, Iran 
and all patients gave a written consent before 
entering the study. The results of best corrected 
visual acuity (BCVA), IOP (measured by 
calibrated Goldmann applanation tonometry), 
slit lamp biomicroscopy, funduscopic 
examination (using a 90 diopter lens), number 
of glaucoma medications and complications 
were recorded for all patients entering the 
study from their medical files. 
The primary outcome in the present study 
was surgical success defined in terms of 
5 ≤ IOP ≤ 21 mmHg and at least 20 % 
reduction in IOP without glaucoma medication 
(complete success), or with medications 
(qualified success). The sum of complete 
success and qualified success was reported 
as cumulative success. Failure was defined 
as IOP < 5 mmHg or more than 21 mmHg in 
at least two consecutive visits, need for AGV 
removal or secondary anti glaucoma surgery 
or visual acuity of no light perception in the 
follow up period. 
Hypertensive phase (HP) was defined as 
IOP > 21 mmHg during the first 3 months 
without tube obstruction or retraction.
Surgical technique
In all patients, the AGV was implanted in 
superotemporal quadrant by three glaucoma 
surgeons according to the same technique. 
After performing a limbal based conjunctival 
flap the AGV (model FP7, New World 
Medical, Rancho Cucamonga, CA, USA) 
was primed, and the plate was secured to the 
sclera with 7-0 silk sutures 8-9 mm behind the 
limbus, then the AGV was inserted into the 
anterior chamber parallel to iris. At this point 
the scleral patch graft was sutured on the tube 
and then conjunctiva was stitched with 10-0 
nylon sutures.  Postoperatively,  all  patients 
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received  chloramphenicol  eye  drops  4 times 
a day for 1 week and betamethasone eye drops 
every 2 hours, which was tapered over the 
next 6 to 8 weeks. Patients were examined 
on the postoperative day 1, then at least 
weekly for 4 weeks, and then every 3 months 
or according to the surgeon’s judgment. Anti 
glaucoma medication was started based on 
surgeon’s decision if the target pressure was 
not achieved in follow up exams.
Results
Twenty three eyes of 23 patients (11 
males and 12 females) with mean age of 
57.08 ± 10.79 years and preoperative visual 
acuity of 1.84 ± 1.07 LogMAR were enrolled 
in this retrospective study. The mean duration 
of follow up was 4.69 years (range, 2-10 
years). We did not include data from patients 
with more than 3 years of follow up since 
we had more than 20 percent of patients lost 
to follow up after the third year. The mean 
preoperative IOP was 33.47 ± 9.61 mmHg, 
and the mean postoperative IOP was 
16.39 ± 7.9 mmHg at year 1, 16.78 ± 7.35 
mmHg at year 2, and 16.95 ± 9.05 mmHg at 
year 3 (P < 0.001) (Table 1). Table 2 shows the 
mean number of anti-glaucoma medications 
pre-surgery and after AGV implantation 
and Table 3 shows the success rate of AGV 
implantation in follow ups up to three years.
Hypertensive phase occurrence was 65 % in 
our patients. Considering complications there 
were 4 cases (17.4 %) with choroidal effusion 
and 2 cases (8.7 %) with AGV exposure.
Discussion 
Neovascular glaucoma (NVG), a complicated 
secondary glaucoma, is caused by retinal 
ischemic diseases 5. Ischemia causes the 
release of angiogenic factors and results in 
neovascularization of the iris and the angle 
5. Nowadays with the increasing number of 
diabetic patients, the number of NVG is also 
increasing accounting for more than 30 % of 
refractory glaucomas 1. In the present study 
we reported the outcome of patients with AGV 
insertion to treat NVG up to three years, which 
is a relatively high follow up period. Complete 
success rate of surgery in our patients was 
17.4 % up to three years postoperatively and 
the cumulative success was 91.3 % at one 
year post operatively, 82.6 % at two years 
postoperatively and 78.3 % at three years 
Table 1: Comparison of the mean intraocular pressure pre-surgery and after AGV 
implantation
Mean IOP Mean ± Std P value * N
Before surgery 33.47 ± 9.61 < 0.001 23
1 month after surgery 14.04 ± 7.03 < 0.001 23
3 months after surgery 15.52 ± 6.52 < 0.001 23
6 months after surgery 15.39 ± 8.27 < 0.001 23
9 months after surgery 15.78 ± 7.02 < 0.001 23
1 year after surgery 16.39 ± 7.9 < 0.001 23
2 years after surgery 16.78 ± 7.35 < 0.001 23
3 years after surgery 16.95 ± 9.05 < 0.001 21
* Wilcoxon Test
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postoperatively. In a previous study by Yalvac 
et al., 14 the cumulative rate of success was 
reported to be 63.2 % at 1 year, 56.2 % at 2 
years, and 43.2 % at 3 years. In another study 
by Netland et al., 15 the success was 73.1 % at 
1 year, 61.9 % at 2 years, and 20.6 % at 5 years. 
Also Shen et al., 16 reported a success rate of 
70 % at 1 year, and 60 % at 2 years after AGV 
insertion in neovascular glaucoma patients.
It seems that our results show a relatively 
higher success rate compared to other studies. 
This might be due to different patient selection 
criteria or success criteria used in different 
studies. 
Considering complications we observed 
choroidal effusion in 17.4 % of our patients. 
In comparison Shen et al., 16 reported 
choroidal effusion in 5 % of their patients, 
Netland et al., 15 reported choroidal effusion 
in 15.8 % and Yalvac et al., 14 reported 
choroidal effusion in 5.3 % of their patients. 
We observed implant exposure in 8.7 % of 
our patients while there was a 5.3 % rate of 
implant exposure in the study by Netland et 
al., 15.
The strength of the present study was its 
relatively long follow up period of three 
years, while it was limited by its retrospective 
methodology and relatively low number 
of participants. More prospective studies 
with higher number of participants are 
recommended to better evaluate the success 
rate of AVG implantation to treat patients with 
neovascular glaucoma.
Conclusion
It seems that AGV insertion is a safe and 
effective surgical method to treat neovascular 
Table 2: Comparison of the mean number of anti-glaucoma medications pre-surgery and 
after AGV implantation 
Mean Number of Medications Mean ± Std P value * N
Before surgery 3.43 ± 0.99 - 23
1 month after surgery 0.43 ± 0.72 < 0.001 23
3 months after surgery 1.04 ± 0.92 < 0.001 23
6 months after surgery 1.39 ± 1.11 < 0.001 23
9 months after surgery 1.69 ± 1.18 < 0.001 23
1 year after surgery 1.73 ± 1.25 < 0.001 23
2 years after surgery 2.13 ± 1.48 0.022 23
3 years after surgery 2.19 ± 1.56 0.024 21
*Chi-Square test
Table 3: The success rate of patients in follow ups up to three years
Success
Variable Fail Fail % Success Success % Total
Year
1 2 8.7 % 21 91.3 % 23
2 4 17.4 % 19 82.6 % 23
3 5 21.7 % 18 78.3 % 23
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glaucoma with acceptable success rates up to 
three years post operatively. More prospective 
studies with higher number of participants are 
recommended to better evaluate the success 
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